Please note – the programme is still preliminary and is subject to change
ISGCT 2027 Preliminary Programme Overview
-
Download ISGCT 2027 Book of Abstracts
-
Download Conference Programme
| DAY 1 - THURSDAY, 21 JANUARY | ||
|---|---|---|
| 08:00 - 10:00 | Registration Open | |
| 08:30 - 09:00 | Posters/Exhibitions/Networking | |
| 09:00 - 09:20 | ISGCT 2027 Opening & Welcome · Society Update |
|
| CAR-T CELL THERAPIES Chairs : Owen Smith CHI |
||
| 09:20 - 09:55 | PL.01 | Genome editing of T cells for cancer immunotherapy Chiara Bonini, San Raffaele Scientific Institute, Milano |
| 09:55 - 10:30 | PL.02 | Metabolism drives (CAR) T cell function Anna Schurich, King's College London |
| Oral Presentations | ||
| 11:15 - 11:30 | O.01 | Metabolic reprogramming enhances stem-like and functional properties of lung cancer-derived TILs Abhishek Tomar, NUIG |
| 11;30 - 11:45 | O.02 | Mesenchymal stromal cells influence the epigenetic landscape of trained macrophages in a clinically relevant model of allergic asthma in vivo Molly Dunlop, Maynooth |
| 11:45 - 12:00 | O.03 | Enhanced retinal pigment epithelial cells as a delivery vehicle for retinal disease Avril Reddy, TCD |
| 12:00 - 12:15 | O.04 | Engineering T cells with synthetic promoter sensors that respond to exhaustion and improve cellular immunotherapy Giuliano Bonfa, NUIG |
| 12:15 - 13:30 | Lunch, Networking & Poster Session | |
| 12:30 - 13:30 | ISGCT AGM The Veranda Room |
|
| Cellular Therapies 2 Chairs : Mikey Creane (HAON) - Sinead Ryan (MU) |
||
| 13:30 - 14:00 | PL.03 | More than just a good experience in CAR-T immunotherapy: Barcelona’s ARI academic program as a model for increasing access Manel Juan, Hospital Clínic de Barcelona |
| 14:00 - 14:30 | PL.04 | Innovations in Stem Cell Research: Unveiling New Therapies for Diabetic (Cardio)vascular Complications Andriana Margariti, Queen’s University Belfast |
| 14:30 - 15:00 | PL.05 | How to engineer robust Natural Killer cell therapies David Finlay, Trinity College Dublin |
| Oral Presentations | ||
| 15:00 - 15:15 | O.05 | SPARCL1 overexpression modulates the repair and protective properties of the MSCs' secretome Aline Morrison |
| 15:15 - 15:30 | O.06 | Identification of Therapeutic Responses of Mesenchymal Stromal Cells Retrieved from Murine Osteoarthritic Joints Mary Murphy, NUIG |
| 15:30 - 16:00 | Refreshments & Networking | |
| Extracellular Vesicles Chairs : Daniel O'Toole (UG) - Claire Masterson (UG) Kindly supported by  |
||
| 16:00 - 16:30 | PL.06 | Extracellular vesicles from iPSC-MSCs as a promising acellular biotherapy for osteoarthritis Daniele Noel, University of Montpellier & University Hospital, Montpellier |
| 16:30 - 17:00 | PL.07 | Mesenchymal Stromal Cell – Extracellular Vesicles for Immunomodulation and Tissue Repair Meadhbh Brennan, School of Engineering & School of Medicine, University of Galway |
| Oral Presentations | ||
| 17:00 - 17:15 | O.07 | Assessing the impact of parent cell genetic modifications to generate visually traceable derivative EVs on EV characteristics and function Hannah Aris, NUIG |
| 17:15 - 17:30 | O.08 | Upstream process development for the biomanufacture of therapeutic MSC-derived extracellular vesicles. Jessica Whelan, UCD |
| 17:30 - 18:00 | Welcome Drink |
| DAY 2 - FRIDAY, 23 JANUARY | ||
|---|---|---|
| 08:00 - 09:30 | Registration Open | |
| Gene Therapy Chairs : Tim O'Brien (UG) - Sinead Kinsella (RCSI) Kindly supported by  |
||
| 09:30 - 10:00 | PL.08 | Gene therapy for cardiovascular diseases and cancer: From basic science to clinical applications Seppo Yla-Herttuala, University of Eastern Finland |
| 10:00 - 10:30 | PL.09 | New Mechanisms — Novel Architectures — Enhanced Performance — Innovative Applications: From Fundamental Research to Advanced Gene and Cell Therapy Wenxin Wang, University College Dublin |
| 10:30 - 11:00 | PL.10 | Delivery of Ocular Gene Therapy. Next Steps in Access for Patients David Keegan, Mater Misericordiae University Hospital |
| 11:00 - 11:30 | Refreshments & Networking | |
| 11:15-11:30 | CONCEPT: A Core Facility Supporting Early-Stage biotherapy Research and Development Clair Gallagher, Manager of CONCEPT  |
|
| Oral Presentations | ||
| 11:30 - 11:45 | O.09 | Cell-selective delivery of nucleic acids for the treatment of glioblastoma Emma McErlean, QUB |
| 11:45 - 12:00 | O.10 | Revolutionizing viral vector production: Biodegradable hyperbranched poly (β-amino ester)-based transfection technology boosts yields and efficiency Xi Wang, Branca Bunus |
| 12:00 - 12:15 | O.11 | Modifying Plasmids and Inverted Terminal Repeats improves Adeno-associated Virus Production and Performance Nicholas Donohue, APC Ltd. |
| 12:15 - 12:30 | O.12 | Can AAV vectors train the innate immune response? Sinead Ryan, Maynooth |
| 12:30 - 12:45 | O.13 | Enhancing AAV Production Yield for Pro-Apoptotic Gene Therapy Using an shRNA Strategy Simeng Li, NIBRT |
| 12:45- 13:45 | Lunch, Networking & Poster Session | |
| Clinical and Patient Perspectives Chairs : Niamh Gilmartin (TUD) - Caomhán Lyons (GU) |
||
| 13:30 - 14:00 | PL.11 | Clinical Perspectives of MSC and Optimized-MSC Therapy: The ‘Spanish Model’ Experience Fermin Sanchez-Guijo, University Hospital of Salamanca |
| 14:00 - 14:30 | PL.12 | Realigning CAR-T therapy use with emerging clinical and biological insights in child and adolescent blood cancers Owen Smith, Children’s Health Ireland and Trinity College Dublin |
| Oral Presentations | ||
| 14:30 - 14:45 | O.14 | New gene(-editing) therapies and Justice – the challenges of access, equity and sustainability Oliver Feeney, University of Tubingen, Germany |
| 14:45 - 15:00 | O.15 | Immune Exhaustion Signatures In CD19 CAR T-Cell Recipients Hayley Foy-Stones, TCD |
| 15:00 - 15:15 | O.16 | Opportunities and challenges of the use of the hospital exemption in the early-stage development of novel cellular therapies Elaine Harris, TU Dublin |
| 15:15 - 15:45 | Closing & Prize Giving |
Main Conference Topics
Advanced Manufacturing and GMP
- AI
- Automation
- Scale Up
Cellular Immunotherapy
- CAR-NK for Haematological Cancers
- CAR-T
- Solid Tumours and Autoimmune Diseases
Company Highlights
- Challenges
- Investment
- Success Stories
Exosomes
- Biology
- Manufacturing and Clinical Trials
Gene Therapy
- Clinical Applications
- Vectors
Session kindly supported by 
Induced Pluripotent Stem Cells
- Disease Modelling
- Drug Screening
- Therapeutic Applications
MSC Therapy
- Biology
- Manufacturing and Clinical Trials
Patient Perspectives
- Patient Perspectives
Regulation
- EU and US Insights
Young Scientist Spotlight
- Young Scientist Spotlight